Selected article for: "Post pre and sEDN change"

Author: Kim, Chang-Keun; Callaway, Zak; Park, Jin-Sung; Nishimori, Hisashi; Ogino, Tikatoshi; Nagao, Mizuho; Fujisawa, Takao
Title: Montelukast Reduces Serum Levels of Eosinophil-Derived Neurotoxin in Preschool Asthma
  • Document date: 2018_8_30
  • ID: uzge50xu_19
    Snippet: Within group analyses of ACD at multiple time points during the entire study period (−2 to 12 weeks) were compared using 2-way ANOVA, followed by Sidak's multiple comparisons test. This was only done for the BIS and MONT groups. Between-group analyses of ACD (BIS versus MONT groups) were done using the Wilcoxon matched-pairs signed rank test. Within group analyses of treatment effect comparing "Pre" (measured during run-in period −2 to 0 week.....
    Document: Within group analyses of ACD at multiple time points during the entire study period (−2 to 12 weeks) were compared using 2-way ANOVA, followed by Sidak's multiple comparisons test. This was only done for the BIS and MONT groups. Between-group analyses of ACD (BIS versus MONT groups) were done using the Wilcoxon matched-pairs signed rank test. Within group analyses of treatment effect comparing "Pre" (measured during run-in period −2 to 0 week) and "Post" (measured at 12 weeks) measurements of changes in sEDN for all 3 groups (BIS, MONT and OBS) were done using the Wilcoxon matched-pairs signed rank test. Each group was then subgrouped according to presence or absence of any virus and change in sEDN with treatment from "Pre" to "Post" was analyzed using the same statistical test. Rescue medication usage within each group (BIS and MONT) and between each group were also compared. Data that were normally distributed were presented as mean values, unless otherwise noted. P values < 0.05 were considered statistically significant. Fig. 2 .

    Search related documents:
    Co phrase search for related documents
    • absence presence and group analysis: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and mean value: 1, 2, 3, 4, 5, 6, 7
    • absence presence and multiple comparison: 1, 2, 3
    • absence presence and multiple comparison test: 1, 2, 3
    • absence presence and Post Pre treatment: 1
    • absence presence and Pre treatment: 1, 2, 3, 4
    • absence presence and rank test: 1, 2, 3
    • absence presence and statistical test: 1, 2, 3, 4, 5, 6, 7
    • absence presence and study period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • absence presence and time point: 1, 2, 3, 4, 5, 6
    • absence presence and treatment effect: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • absence presence and virus absence presence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
    • ANOVA compare and group analysis: 1, 2
    • ANOVA compare and multiple comparison: 1, 2, 3, 4
    • ANOVA compare and multiple comparison test: 1, 2
    • ANOVA compare and rank test: 1, 2
    • ANOVA compare and statistical test: 1, 2, 3, 4
    • ANOVA compare and time point: 1, 2
    • ANOVA compare and treatment effect: 1